Premium
Antibody to Herpesvirus hominis types 1 and 2 in patients with hodgkin's disease and carcinoma of the nasopharynx
Author(s) -
Catalano Louis W.,
Goldman John M.
Publication year - 1972
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197203)29:3<597::aid-cncr2820290311>3.0.co;2-h
Subject(s) - antibody , medicine , titer , nasopharyngeal carcinoma , incidence (geometry) , antibody titer , disease , carcinoma , pathology , immunology , virology , radiation therapy , physics , optics
Sera from 40 patients with Hodgkin's disease and 20 patients with nasopharyngeal carcinoma (NPC) were studied for neutralizing antibodies to both strains of Herpesvirus hominis (HVH). A greater incidence of type 2 HVH antibody was found in male patients with Hodgkin's disease compared with age‐matched blood donor controls. A possibly greater incidence of type 2 HVH antibody was observed in all patients with Hodgkin's disease. Patients with a mixed cellular histologic type had a greater incidence of type 2 HVH antibody. No significant increase in geometric mean antibody titers to either strain of HVH was observed in this disease. Although there was no increased incidence of either type of HVH antibody in patients with NPC, individuals with NPC had higher serum titers to the type 2 strain of HVH than did blood donor controls. No titer differences were found when patients with NPC were compared to patients with head and neck tumors. The study suggests that additional information is necessary to clarify the role of type 2 HVH in Hodgkin's disease. An altered immunologic reactivity is proposed as a basis for the elevated titers to the type 2 strain of HVH in patients with NPC.